Abstract Number: 1551 • ACR Convergence 2021
Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination
Background/Purpose: The rapid spread of the COVID-19 pandemic has created the need for mass vaccination of patients with autoimmune rheumatic disease (AIIRD) despite the lack…Abstract Number: 1562 • ACR Convergence 2021
B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab
Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…Abstract Number: 0104 • ACR Convergence 2021
Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population
Background/Purpose: Clinical trials on efficacy and safety of SARS-CoV-2 vaccines did not include patients with autoimmune diseases. We previously demonstrated that concerns of adverse events…Abstract Number: 1589 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy in Rheumatology Patients
Background/Purpose: Patients with rheumatic diseases on certain immunosuppressant medications are known to be at higher risk for severe COVID-19. The ACR recommends COVID-19 vaccination for…Abstract Number: 0113 • ACR Convergence 2021
Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
Background/Purpose: Little is known about the reactogenicity and related SARS-CoV-2 vaccine response in patients with chronic inflammatory disease (CID). While researchers have hypothesized increased symptomatology…Abstract Number: 1603 • ACR Convergence 2021
COVID-19 Vaccination Experience in Patients with Rheumatoid Arthritis Treated at the Cleveland VA Medical Center
Background/Purpose: Following the introduction of the COVID-19 vaccines, there has been uncertainty as to whether receiving the COVID-19 vaccine would result in overactivation of the…Abstract Number: 0390 • ACR Convergence 2021
Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Background/Purpose: COVID-19 vaccination is recommended for individuals with rheumatic diseases, yet data are limited regarding vaccine safety in this population, particularly among those with rare…Abstract Number: 1607 • ACR Convergence 2021
The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE
Background/Purpose: The ACR has issued guidance recommending COVID-19 vaccine for all patients with rheumatic diseases. Vaccine hesitancy research prior to the COVID-19 pandemic has demonstrated…Abstract Number: 0457 • ACR Convergence 2021
Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…Abstract Number: 0640 • ACR Convergence 2021
Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors
Background/Purpose: Tumor necrosis factor α inhibitors (TNFi) predispose to bacterial infections including pneumonia. In turn, vaccination with pneumococcal 13 valent (PCV13) and pneumococcal 23 valent…Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…Abstract Number: 0649 • ACR Convergence 2021
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…Abstract Number: 0964 • ACR Convergence 2021
Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases
Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…Abstract Number: 0983 • ACR Convergence 2021
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…
ACR Meeting Abstracts